Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine

Pfizer Inc.Pfizer Inc. (NYSE: PFE) announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program. The AMC is an innovative program which involves private-public partnerships to help make newer vaccines available on a sustainable, affordable and accelerated basis to the least developed countries.

"Pfizer remains steadfast in its commitment to accelerate global access to its vaccines and medicines; public-private partnerships such as those that underpin the AMC are a great example of how to make critical progress in that area," says Mark Swindell, president, Pfizer Vaccines. "It truly is historic to see a new vaccine such as Prevenar 13 launched in a developing country within one year of its introduction in the U.S. and Europe, given the previous average 15-year gap between introduction of new vaccines in developed and developing countries."

Prevenar 13 provides coverage against the 13 most prevalent invasive pneumococcal disease-causing strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in infants and young children worldwide. Prevenar 13 is the only pneumococcal conjugate vaccine available under the AMC that is prequalified by the World Health Organization (WHO) for use in children through 5 years of age and to help prevent pneumonia caused by the 13 serotypes contained in the vaccine.

About the AMC
In March 2010, Pfizer entered into a 10-year agreement to provide Prevenar 13 to infants and young children in the world's poorest countries under the terms of the AMC for pneumococcal disease.

A new approach to public health funding, the AMC, which is administered by the GAVI Alliance, is designed to procure vaccines specifically for least developed countries. In this pilot AMC for PD, the governments of Italy, the United Kingdom, Canada, the Russian Federation and Norway as well as the Bill and Melinda Gates Foundation, the World Bank, and GAVI have committed financing.

In addition, this novel program is a reflection of the dedication and commitment of organizations such as the GAVI Alliance, the World Bank and other public health organizations.

"This innovative new model is poised to drive accelerated access to potentially lifesaving vaccines for millions of children in the world's poorest countries, where PD exacts its greatest toll," adds Mr. Swindell. "It's a great example of how creative partnerships can result in solutions for some of the most pressing public health issues."

Pneumococcal Disease
PD is complex and describes a group of illnesses, all caused by the bacterium Streptococcus pneumoniae (S. pneumoniae). It includes invasive infections such as bacteremia and meningitis, as well as non-invasive disease including pneumonia and acute otitis media.

Prevenar 13 is marketed in the United States as Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]). In the United States, Prevnar 13 is not indicated for the prevention of pneumonia.

Indication for Prevnar 13® in the United States
In the United States, Prevnar 13 is a vaccine approved for use in children 6 weeks through 5 years of age (prior to the sixth birthday). Prevnar 13 is indicated for active immunization for the prevention of invasive disease caused by 13 strains of S. pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Prevnar 13 is also indicated for the prevention of otitis media (ear infection) caused by seven strains of S. pneumoniae (4, 6B, 9V, 14, 18C, 19F, and 23F). No efficacy data for ear infections are available for strains 1, 3, 5, 6A, 7F, and 19A.

World Health Organization Indication for Prevenar 13
Earlier this year, the World Health Organization (WHO) prequalified Prevenar 13 for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the vaccine. WHO prequalification allows for the procurement of Prevenar 13 by United Nations agencies. The prequalification is for global use of the vaccine in a single-dose vial.

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Novartis teams up with Harvard to develop next gen…

Novartis announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Can...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...